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SUMMARY. Background. Granulosa cell tumors (GCTs) are rare neoplasms and they represent about 2 to 5% of all ovarian 
cancers. They are usually detected at an early stage and have a relatively favorable prognosis. Aim. The aim of this study 
was to investigate the clinical and pathological characteristics of GCT patients and to identify the prognostic factors. 
 Methods. In a retrospective study, we have analyzed the medical data of 18 patients with newly diagnosed GCTs treated by 
the Department of Gynecology and Obstetrics in the University Hospital Centre Zagreb in the period from January 2011 
until December 2017. We have investigated data for age, parity, symptoms, tumor size, stage of disease, radicality of sur-
gery, pathological characteristics of the tumors (number of mitosis, presence of Call-Exner bodies), application of adjuvant 
chemotherapy, time to progression of disease and overall survival. Results. Data from 18 cases were obtained. The median 
age was 55 years. The mean parity was 1,39. The most common clinical manifestations of the disease were abdominal pain 
(44%) and abdominal distension (44%). The mean tumor size was 11 cm (range 2 – 30 cm). The majority of our patients 
were stage I (78%, N = 14), while (22%, N = 4) were stage III. 15 patients underwent radical surgery, while in 3 patients 
fertility-sparing surgery was performed. According to the tumor characteristics, the mitotic count was high (> 10 mitosis/10 
HPFs) in 9 cases (50%) and 7 patients had presence of Call-Exner bodies. Four patients received 1–6 cycles of adjuvant 
chemotherapy. During the follow-up period (median 49 months), 3 patients relapsed and one patient died free of the pri-
mary disease, from myocardial infarction. Conclusion. The basis of therapy in GCTs is surgical removal of the disease, and 
platinum-based adjuvant chemotherapy is recommended for advanced-stage GCTs. A prolonged follow-up period is neces-
sary because they progress slowly and have a specifi c tendency for late recurrences.
Introduction
Granulosa cell tumors (GCTs) are rare ovarian malig-
nancies that represent 2–5% of all ovarian cancers. They 
were described for the fi rst time in 1855 by Rokitansky 
(1). These tumors are part of ovarian sex-cord stromal tu-
mors (SCST). They arise from hormonally active granu-
losa cells and secrete different substances such as estro-
gen, inhibin, anti-Müllerian hormone which are used as 
serum tumor markers. According to their clinical and his-
tological features GCTs are divided into two subtypes: 
adult type (95%) and juvenile type (5%). Juvenile GCTs 
usually occur in women younger than 30 years, while the 
median age of diagnosis for the more common adult GCTs 
is between 50 and 54 years (2,3). The basis of therapy in 
GCTs is surgical removal of the disease. A total abdominal 
hysterectomy and bilateral salpingo-oophorectomy is rec-
ommended. In young patients with FIGO stage I disease, 
who wish to preserve fertility, a unilateral salpingo-oopho-
rectomy can be an option. Adjuvant platinum-based che-
motherapy or radiotherapy for limited disease is recom-
mended in patients with advanced stages of disease (stage 
II-IV) and we can consider the use of the chemotherapy in 
patients with high risk stage IC disease. Prolonged surveil-
lance is recommended because they can occur years later 
(even after 40 years) (4–6). The aim of our study presented 
here was to report clinical and pathological characteristics, 
treatment and outcomes of patients with ovarian GCTs 
treated at our hospital.
Methods
We have analyzed medical data of eighteen patients 
with adult type granulosa cell tumors of the ovary. All 
these patients were treated by the Department of Gynecol-
ogy and Obstetrics in the University Hospital Center Za-
greb in the period from January 2011 until December 
2017. We have investigated data for age, parity, symptoms, 
tumor size, stage of disease, radicality of surgery, patho-
logical characteristics of the tumors (number of mitosis, 
presence of Call-Exner bodies), application of adjuvant 
chemotherapy, time to progression of disease and overall 
survival. Patients were followed up until March 2018. 
Quantitative variables were expressed as mean and median 
values. Qualitative variables are expressed as absolute and 
relative frequencies.
Results
Eighteen cases with histologically confi rmed GCTs of 
the ovary were identifi ed during a period between January 
2011 and December 2017. The median age was 55 years 
(range 26 – 84 years). For 89% of the patients (N=16), the 
tumor occurred between the fi fth and ninth decade of life. 
The mean parity was 1.39, and 12 of the patients were 
menopausal. The most common clinical manifestations of 
the disease were abdominal pain (44%) and abdominal 
distension (44%). Other symptomatology included post-
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Table 1. Characteristics of the patients
Characteristics (N=18) N (%)









Pelvic/abdominal pain 8 (44%)
Abdominal distension 8 (44%)
Postmenopausal bleeding 5 (28%)
Secondary amenorrhea 1 (6%)
FIGO stage of disease
Stage I 14 (78%)
IA 9 (50%)
IC 5 (28%)




(5,5%). Fractional curettage was performed before opera-
tion in 5 patients (one patient had an orderly pathohisto-
logical fi nding, two were diagnosed with endometrial 
 polyps, and two with endometrial hyperplasia). Preopera-
tive values of inhibin B were not studied in any of our pa-
tients. A summary of patients’ characteristic is presented in 
Table 1.
The mean tumor size was 11 cm (range 2 – 30 cm). The 
majority of our patients were stage I (78%, N = 14), while 
(22%, N = 4) were stage III. The primary treatment was 
surgery in all cases. Out of 18 patients, 15 patients (83%) 
underwent a radical surgery which included hysterectomy 
with bilateral salpingo-oophorectomy, omentectomy, peri-
toneal biopsies and abdominal washout. Lymphadenecto-
my was done in three patients. Three patients underwent a 
conservative surgery, which included unilateral salpingo-
oophorectomy in two patients (11%) and cystectomy in 
one patient (5%). Two patients had a rupture of the tumor 
in the intraoperative fi nding and two patients had a cystic 
rupture during the operative procedure. In four patients 
(22%) the presence of malignant cells was found in perito-
neal fl uid. Postoperatively, in one patient was found simul-
taneously endometrial adenocarcinoma, which was stage 
I, gradus I and did not require further therapy. According 
to the tumor characteristics, the mitotic count was high (> 
5 mitosis/10 HPFs) in 9 cases (50%) and 7 patients had 
presence of Call-Exner bodies. A summary of tumor char-
acteristic is presented in Table 2.
We recommended adjuvant chemotherapy for fi ve pa-
tients (one with stage FIGO IC and four with stage III) and 
only four patients received 1–6 cycles of postoperative 
chemotherapy. Adjuvant chemotherapy was a platinum-
based regimen: CEP (cyclophosphamide 600 mg/m2D1, 
Table 2. Characteristics of the tumor
N (%)
Size of the tumor
≤10 cm 10 (56%)











– preoperatively 2 (11%)





Not measured 2 (11%)
epirubicin 70 mg/m2 D1 plus cisplatin 50 mg/m2 D1 every 
4 weeks) in 1 patient and PEB (cisplatin 20 mg/ m2 D1-D3, 
bleomycin 20 mg/ m2 (max 30 mg) D2,D9,D16 and etopo-
side 100 mg/ m2 D1-D5 every 3 weeks) in 3 patients. No 
patient received adjuvant radiotherapy or hormonal thera-
py. The median follow-up period was 49 months. During 
this period, recurrence was observed in three patients 
(16%), and the mean time from initial surgery to recur-
rence was 47 months (range 30 to 70 months). The site of 
relapse was pelvis in all three patients, and one had also 
retroperitoneal lymph nodes involvements. In all patients a 
surgery was done and one patient received chemotherapy 
with PEB regimen, others refused administration of che-
motherapy. They are still alive, two of them are without 
recurrence of the disease and one patient had second recur-
rence, also in the pelvis. She has had a surgery and now 
has received the second line chemotherapy with paclitaxel 
and carboplatin. One patient died free of the primary dis-
ease, from myocardial infarction. The median overall sur-
vival has not yet been reached. 5-year survival in our study 
is 94%. A summary of patients’ characteristic with recur-
rent disease is presented in Table 3.
Discussion
Granulosa cell tumors (GCTs) are rare malignancies 
with a good prognosis. In our study we included only eigh-
teen patients in the period from January 2011 until Decem-
ber 2017. GTCs are the most common type of ovarian sex-
cord stromal tumors. They are divided into two subtypes: 
adult type and juvenile type. Adult type GCTs are more 
common and usually occur in peri-menopausal and post-
menopausal women (the median age 50–55 years). Juve-
nile GCTs are less common and they comprise 5 percent of 
all GCTs. This type usually occurs in pre-menarche girls 
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and young women (2,3). The distinction between these 
two subtypes is further aided by the presence of a specifi c 
somatic missense mutation in FOXL2 gene in adult GCTs, 
which is typically absent in juvenile GCTs. FOXL2 gene 
encodes a transcription factor necessary for normal granu-
losa-cell development (7). In our study, the median age of 
patients was 55 years.
They are different from the epithelial ovarian cancer be-
cause they produce estrogen and/or progesterone and have 
a different nature of presentation and clinical behavior (8). 
Compared to epithelial ovarian cancers, the clinical course 
of GCTs is more indolent (slower peritoneal spread) lead-
ing to a large tumor size at the time of diagnosis confi ned 
to the ovary. The most reported signs are abdominal pain 
and abdominal distension but menstruation problems can 
also occur like intermenstrual bleeding or other menstrual 
irregularities, postmenopausal bleeding or amenorrhea 
(9–14). In our study, the most common symptoms were 
abdominal pain (44%) and abdominal distension (44%) 
and then postmenopausal bleeding (27%) and secondary 
amenorrhea (5.5%).
Abnormal uterine bleeding is caused by the exposure of 
the endometrium to tumor-derived estrogen (9,10). This 
excessive and prolonged exposure to estrogen may cause 
endometrial hyperplasia and endometrial carcinoma. For 
this reason, preoperative endometrial biopsy is suggested 
in all women with abnormal uterine bleeding. Endometrial 
Figure 1. Treatment modalities in our patients







treatment PFI (months) Site of relapse Treatment of relapse
1 82 IIIC2 4 Surgery + CTH 
(1xCEP)
40 Retroperitoneal + pelvic surgery
(refused postoperative CTH)
2 63 IC 7 surgery 30 pelvic Surgery + CTH




CTH=chemotherapy, PFI= progression free interval
adenocarcinoma can be found simultaneously in 5–10% of 
patients with granulosa cell tumor and are often well-dif-
ferentiated and in an early stage with a favorable prognosis 
(15). Fractional curettage was performed before operation 
in 5 of our patients. One patient had an orderly pathohisto-
logical fi nding, two were diagnosed with endometrial 
 polyps and two with endometrial hyperplasia. Preopera-
tively, none of the patients was diagnosed with endome-
trial cancer.
The average size usually reported in literature is more 
than 10 cm (11–14). The average tumor size of our patients 
was 11 cm (range 2–30 cm).
Diagnosis of the GCTs is made by histology at the time 
of surgical excision. Preoperatively, ultrasound evaluation 
usually reveals a large solid ovarian mass with variable 
number of cysts and absent papillary projections. They 
arise from hormonally active granulosa cells and secrete 
different substances such as estrogen, inhibin, anti-Mülle-
rian hormone which are used as serum tumor markers (16). 
Preoperative values of inhibin B were not studied in any of 
our patients. Serum CA-125 is not correlated to this tumor.
The mainstay of initial management is a surgery which 
includes hysterectomy, bilateral salpingo-oophorectomy 
and removal of all gross disease (17). Nodal dissection is 
not recommended in surgical staging of GCT (18). GCTs 
are staged surgically according to the International Federa-
tion of Gynecology and Obstetrics (FIGO) staging system 
(19). The majority of patients initially present with stage I 
disease (65–80%) (11–13, 20). Similar results were ob-
tained in our study, 78% (N=14) of our patients were FIGO 
stage I, while 22% (N=4) were FIGO stage III.a.
While in women who are done with childbearing total 
abdominal hysterectomy and bilateral salpingo-oophorec-
tomy are typically performed, in younger women wishing 
to preserve fertility a unilateral salpingo-oophorectomy 
with careful staging should be performed. In the early 
stages of the disease (FIGO IA), retrospective studies sug-
gest a similar cure rate whether treated by a fertility-pre-
serving surgery or a complete surgery (20). In these pa-
tients where fertility-preserving surgery is performed, en-
dometrial biopsy is recommended to rule out concomitant 
uterine disease. Out of 18 of our patients, 15 patients un-
derwent radical surgery. Lymphadenectomy was done in 
three patients. Three patients underwent a conservative 
surgery, which included unilateral salpingo-oophorectomy 
in two patients and cystectomy in one patient (she refused 
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more radical surgery). Postoperatively, in one of the pa-
tients was found simultaneously endometrial adenocarci-
noma, which was in an early stage with a favorable prog-
nosis and did not require further therapy. The percentage 
of simultaneous occurrence of endometrial carcinomas in 
our study is 6 %, which is similar to the occurrence in oth-
er studies (15).
Although the survival of patients with GCTs is generally 
excellent as they mostly present at an early-stage disease, 
certain patients at high risk of recurrence and disease-re-
lated death may be identifi ed. For most patients with an 
early stage of disease, surgery alone is an acceptable treat-
ment. Although, the benefi t of postoperative treatment for 
women with stage IC to IV disease is unclear, adjuvant 
platinum-based chemotherapy or radiotherapy for limited 
disease is recommended in patients with advanced stages 
of disease (stage II-IV) and we can consider the use of the 
chemotherapy in patients with a high risk stage IC disease 
(whose tumor has ruptured, has nuclear atypia, or a high 
mitotic index) (15, 21). Regimens used for GCTs are main-
ly platinum-based with combinations of other agents such 
as bleomycin, cisplatin, etoposide, vinblastine, doxorubi-
cin and cyclophosphamide (22). The most preferred regi-
men is a combination of bleomycin, etoposide, and cispla-
tin (BEP), but alternative chemotherapy regimens are 
bleomycin, vinblastine and cisplatin (BVP), etoposide and 
cisplatin (EP), cyclophosphamide, doxorubicin and cispla-
tin (CAP), and lately paclitaxel and carboplatin (PC). The 
reported response rates to these chemotherapy regimens 
have varied signifi cantly from 20–100% (23–25). We rec-
ommended adjuvant chemotherapy for fi ve patients and 
only four patients received 1–6 cycles of postoperative 
chemotherapy. Adjuvant chemotherapy was a platinum-
based regimen: CEP regimen in one patient and three pa-
tients received chemotherapy per PEB regimen. No patient 
received adjuvant radiotherapy.
The role of adjuvant chemotherapy is still unclear. Some 
retrospective studies showed longer progression free inter-
val (PFI) and overall survival (OS) in patients with ad-
vanced stage GCTs, who received adjuvant chemotherapy 
(26), and other studies did not show the same benefi t (24).
The prognosis of patients with GCTs depends primarily 
on the stage of disease and the presence of residual disease 
after surgery (24,27,28). The others potential prognostic 
factors are age, tumor size, absence of lymph nodes inva-
sion (20,28,29), but their signifi cance has not been demon-
strated in all studies. Cellular atypia, mitotic rate and the 
absence of Call-Exner bodies are identifi ed like the only 
pathologic prognostic factors (29,30). According to the tu-
mor characteristics, the mitotic count was high (> 5 mito-
sis/10 HPFs) in 9 cases and 11 patients had absence of 
Call-Exner bodies, but because of a small number of pa-
tients and a short time of follow-up period, we have not 
analyzed the effect of these factors on PFI and OS.
Around a quarter to third of all patients develop recur-
rent tumors and require further treatment (11). One third of 
recurrences occur more than 5 years following the initial 
treatment, and one fi fth after 10 years, but occasionally 
they can also occur after more than 25 years (5,6). A com-
mon place for the tumor to recur is the pelvis with 30–45% 
of patients having local pelvic recurrence only. In 55–70% 
of patients, however, at the time of diagnosis the tumor has 
already spread extrapelvically and usually involves perito-
neal surface. Distant metastases are generally rare (29). 
Stage is the only clinical factor unequivocally related to 
recurrence with a higher risk of relapse shown in stages II 
to IV of the disease (24,27–29). There is no standard treat-
ment of recurrent disease. If it is possible, a complete tu-
mor resection should be done. In patients with a metastatic 
or suboptimally cytoreduced disease, a platinum-based 
chemotherapy is an option. Platinum-based chemotherapy 
is also an option in postoperative settings. Regimens used 
for recurrent GCTs are the same like in adjuvant setting, 
but the choice of chemotherapy depends on ECOG perfor-
mance status and comorbidities of patients, prior therapy 
and patient’s wishes. If a patient is chemotherapy naive, 
PEB is the regimen of choice. If a patient has received 
PEB in adjuvant setting, some other chemotherapy regi-
men is recommended because of the pulmonary toxicity of 
the bleomycin (31). Other options for patients with recur-
rent GCTs are a radiation therapy or a hormonal therapy 
(tamoxifen, progesterone, combination of tamoxifen and 
progesterone or aromatase inhibitors). Antiangiogenic 
therapy (bevacizumab) also has a promising role in the 
treatment of the recurrent GCTs (32). In our study, recur-
rence was observed in three patients (16%) in the mean 
follow-up period of 49 months. In all patients with recur-
rence, a surgery has been done and one patient received 
chemotherapy with PEB regimen. They are still alive, one 
of them had a second recurrence and she has undergone a 
complete tumor resection and now has received the second 
line chemotherapy with paclitaxel and carboplatin.
The reported 5-year survival for patients with stage I is 
greater than 90%, while for patients with stage II tumors 
5-year survival is reduced to 55–75% and for patients with 
stage III/IV to 22–50%. More than 70% of women with 
recurrent disease die from their disease. (30,33,34)
Only one of our patients died free of the primary dis-
ease, from myocardial infarction. The median overall sur-
vival has not yet been reached and a 5-year survival is 
94%.
For treatment response assessment and follow-up differ-
ent tumor markers have been in use, with inhibin and anti-
Müllerian hormone found to be more reliable markers of 
disease activity than estradiol. Inhibin as a polypeptide 
hormone produced by granulosa cells is secreted mostly in 
follicular phase of the menstrual cycle, while in postmeno-
pausal women inhibin levels should be low. Anti-Mülleri-
an hormone is also secreted during the reproductive period 
and becomes undetectable in postmenopausal women. Re-
ported studies show elevated levels of both inhibin and 
anti-Müllerian hormone in women with active GCTs. The 
clinical utility of these markers is still, however, under de-
bate due to a high risk of bias in these studies (35).
After primary therapy, a prolonged surveillance is indi-
cated. Usually it is a recommendation to control tumor 
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markers and to do a clinical examination. Radiographic 
imaging is performed only if clinically indicated.
Conclusion
The basis of therapy in GCTs is a surgical removal of 
the disease, and platinum-based adjuvant chemotherapy is 
recommended for advanced-stage GCTs. A prolonged fol-
low-up period is necessary because they progress slowly 
and have a specifi c tendency for late recurrences.
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GRANULOZA STANIČNI TUMORI JAJNIKA: 
RETROSPEKTIVNA ANALIZA 18 SLUČAJEVA
Joško Lešin1, Kristina Katić1, Nina Kosi1, Dina Lešin2
Stručni članak
Ključne riječi: rak jajnika, granuloza stanični tumori, ishodi, liječenje
SAŽETAK. Uvod. Granulozna stanični tumori (GST) rijetke su neoplazme i predstavljaju oko 2 – 5% svih karcinoma 
jajnika. Uobičajeno se otkrivaju u ranoj fazi bolesti i imaju relativno povoljnu prognozu. Cilj ovog istraživanja bio je 
opisati kliničke i patološke karakteristike pacijentica s GST-ovima i utvrditi prognostičke čimbenike. Metode. Retro-
spektivnim istraživanjem analizirali smo medicinske podatke 18 bolesnica s novootkrivenim GST-ovima liječenih u 
Klinici za ženske bolesti i porode KBC-a Zagreb u razdoblju od siječnja 2011. do prosinca 2017. godine. Analizirani su 
dob, paritet, simptomi, veličina tumora, stadij bolesti, opsežnost operativnog zahvata, patološke karakteristike tumora 
(broj mitoza, prisutnost Call-Exnerovih tjelašaca), primjena adjuvantne kemoterapije, vrijeme do progresije bolesti i 
preživljenje. Rezultati. Dobiveni su podatci od 18 bolesnica. Srednja dob uključenih bolesnica bila je 55 godina. Medi-
jan broja porođaja bio je 1,39. Najčešće kliničke manifestacije bolesti bile su abdominalna bol (44%) i abdominalna 
napetost (44%). Prosječna veličina tumora bila je 11 cm (raspon 2–30 cm). Većina naših bolesnica bila u I. stadiju bole-
sti (78%, N = 14), dok ih je manji dio (22%, N = 4) bio III. stadija bolesti. Od svih, 15 bolesnica podvrgnuto je radikal-
noj operaciji, dok je u tri bolesnice izvršena poštedna operacija s ciljem očuvanja plodnosti. Prema karakteristikama 
tumora, broj mitoza bio je visok (> 10 mitoza / 10 HPF) u 9 slučajeva (50%), a 7 bolesnica imalo je prisutnost 
 Call-Exnerovih tjelešaca. Četiri bolesnice primile su 1–6 ciklusa adjuvantne kemoterapije. Tijekom perioda praćenja 
(medijan 49 mjeseci), 3 bolesnice imale su recidiv bolesti, a jedna bolesnica umrla je nevezano uz osnovnu bolest, od 
infarkta miokarda. Zaključak. Temelj terapije GST-ova kirurško je odstranjenje bolesti, a u uznapredovalim stadijima i 
primjena adjuvantne kemoterapije na bazi platine. Potrebno je dugotrajno praćenje bolesnica jer bolest obično napreduje 
sporo i ima tendenciju pojave kasnih recidiva.
